Short answer
Relay Therapeutics, Inc. (RLAY) filed an 8-K current report with the SEC on June 9, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.07 (Submission of Matters to a Vote of Security Holders). Authorized common shares increased from 300 million to 450 million.
Relay Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Authorized common shares increased from 300 million to 450 million
- Stockholder approval received at the 2026 Annual Meeting
- Greater issuance capacity supports potential financing, acquisitions, equity compensation, or other corporate purposes
- Potential future share issuance could dilute existing stockholders
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Class III directors Douglas S. Ingram and Claire Mazumdar re-elected through 2029
- Executive compensation approved advisory basis, 143,849,919 votes for
- Ernst & Young LLP appointment ratified for fiscal 2026, 171,030,133 votes for
- Authorized common shares increased from 300,000,000 to 450,000,000
- Share increase expands future financing and equity issuance capacity, with potential dilution risk for existing holders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Relay Therapeutics, Inc. 8-K filings
Get the next RLAY 8-K as it lands
Follow RLAY for push alerts, or ask the research agent what this filing means.